Nikolaos Papadantonakis

Emory University — United States

Medicine · Health Sciences

16h-index1.2kcitations59works8.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(28), Myeloproliferative Neoplasms: Diagnosis and Treatment(16), Chronic Myeloid Leukemia Treatments(13), Acute Lymphoblastic Leukemia research(12), CAR-T cell therapy research(6)

Publications59 total

Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity
Journal of Biological Chemistry·2025Open Access
Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities
Journal of Personalized Medicine·2025· 3 citedOpen Access
Trans-differentiation of plasma cell neoplasm to acute myeloid leukemia with monocytic features: Case report of divergent phenotype with identical genotype
Leukemia Research Reports·2025Open Access
Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity
2024Open Access
Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
Blood·2024· 1 citedOpen Access
Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives
Cancers·2024· 3 citedOpen Access
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
The Lancet Oncology·2024· 54 citedOpen Access
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
Cancers·2024· 12 citedOpen Access
Pure Red Cell Aplasia
2024
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Haematologica·2022· 13 citedOpen Access
Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management
Laboratory Medicine·2022· 6 cited
AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker
Scientific Reports·2022· 14 citedOpen Access
AKR1C3 Expression in T and B Acute Lymphoblastic Leukemia/Lymphoma for Clinical Use as a Biomarker
Research Square (Research Square)·2021Open Access
Immunotherapies for Myelodysplastic Syndromes: Current State and Future Developments
Erciyes medical journal·2021Open Access
MPN-038: Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study
Clinical Lymphoma Myeloma & Leukemia·2020· 9 citedOpen Access
Acute Myeloid Leukemia Case Harboring Unusual <i>FLT3</i> Variant: Somatic vs Germline?
Laboratory Medicine·2020
Integrating touchscreen-based geriatric assessment and frailty screening for adults with acute myelogenous leukemia to drive personalized treatment decisions.
Journal of Clinical Oncology·2020
Nuclear power development in Greece
Dione (University of Piraeus)·2020Open Access
Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts
Therapeutic Advances in Hematology·2020· 30 citedOpen Access
Central Nervous System Double Relapse of Acute Promyelocytic Leukemia and Acute Myelomonocytic Leukemia
Case Reports in Hematology·2019· 1 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Harry P. Erba(10), Eunice S. Wang(8), Daniel J. DeAngelo(7), Anjali S. Advani(7), Katya Ravid(6), Callum M. Sloss(6), Patrick A. Zweidler‐McKay(6), Alexia Eliades(5), Naval Daver(5), Naveen Pemmaraju(5), Marina Konopleva(5), Hagop M. Kantarjian(5), Catriona Jamieson(4), Philip C. Trackman(4), Shinobu Matsuura(4), Kerry Culm-Merdek(4), Gaurav Shah(4), Fady M. Mikhail(4), Ruben A. Mesa(3), Aaron T. Gerds(3)